Aarti Pharmalabs Limited (NSE:AARTIPHARM)

Market Cap	82.40B
Revenue (ttm)	21.15B
Net Income (ttm)	2.72B
Shares Out	90.63M
EPS (ttm)	30.04
PE Ratio	30.27
Forward PE	n/a
Dividend	3.50 (0.38%)
Ex-Dividend Date	Feb 14, 2025

Volume	242,116
Average Volume	534,075
Open	929.00
Previous Close	925.25
Day's Range	906.05 - 933.55
52-Week Range	536.55 - 949.50
Beta	-0.41
RSI	64.30
Earnings Date	May 12, 2025

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medication...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,095
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In 2024, Aarti Pharmalabs's revenue was 21.15 billion, an increase of 14.17% compared to the previous year's 18.53 billion. Earnings were 2.72 billion, an increase of 25.59%.